ライフサイエンスコーパス: after stopping

1 years of immunotherapy (approximately 1 year after stopping).

2 e smoking-attributed risk more than 10 years after stopping.

3 ping 1.16 [1.08-1.23], 2p=0.00001; 5-9 years after stopping 1.07 [1.02-1.13], 2p=0.009).

4 sers 1.24 [1.15-1.33], 2p<0.00001; 1-4 years after stopping 1.16 [1.08-1.23], 2p=0.00001; 5-9 years a

5 eflux disease experience symptomatic relapse after stopping acid-suppressive medication.

6 Gains were largely maintained 48 weeks after stopping alendronate.

7 commonly occur in lung transplant recipients after stopping anti-CMV prophylaxis.

8 responds to antibiotics but relapses shortly after stopping antibiotics (also known as "chronic antib

9 The unadjusted risk ratio for recurrent VTE after stopping anticoagulant therapy in patients with an

10 , and/or d-dimer testing is positive 1 month after stopping anticoagulant therapy.

11 itant proximal DVT), a positive d-dimer test after stopping anticoagulation, an antiphospholipid anti

12 The risk of relapsing into depression after stopping antidepressants is high, but no establish

13 number of discontinuation symptoms at week 1 after stopping antidepressants was below the threshold f

14 dividuals who maintain low levels of viremia after stopping antiretroviral therapy (ART).

15 h HIV experience a quick return of the virus after stopping antiretroviral therapy (ART).

16 Within 6 weeks after stopping antiretroviral therapy, each patient expe

17 biomarkers can predict time to viral rebound after stopping ART by analysing data from a randomized s

18 how HIV and cellular gene expression change after stopping ART in both noncontrollers and posttreatm

19 al [ART] therapy; n = 2 with rebound viremia after stopping ART), who provided serial blood samples b

20 pient MCMs that remained aviremic >2.5 years after stopping ART, in other cases, it was insufficient

21 After stopping ART, the plasma viral load (PVL) in the c

22 ion as well as the viral rebound that occurs after stopping ART.

23 ion as well as the viral rebound that occurs after stopping ART.

24 ed individuals who did not control the virus after stopping ART.

25 w transmission and spread, including rebound after stopping ART.

26 Two hours after stopping behavioral experiments, we euthanized rat

27 After stopping beta-blocker treatment, the median increa

28 m improvement in maximal functional capacity after stopping beta-blocker treatment.

29 " remained free of HIV rebound over a decade after stopping cART.

30 Five relapsed after stopping CBZ treatment and were rendered euthyroid

31 ing of adverse events in the initial 90 days after stopping clopidogrel among both medically treated

32 for death or MI in the 0- to 90-day interval after stopping clopidogrel compared with the 91- to 365-

33 bound of platelet activity to above baseline after stopping clopidogrel in patients with stable coron

34 rval: [CI])/1,000 person-days of death or MI after stopping clopidogrel in the time intervals of 0 to

35 idogrel treatment, the first 90-day interval after stopping clopidogrel treatment was associated with

36 ays, and 6.5% (n = 8) during 181 to 270 days after stopping clopidogrel treatment.

37 e needed to confirm the clustering of events after stopping clopidogrel, including associations with

38 2009, followed for all-cause mortality or MI after stopping clopidogrel.

39 rease in inflammation markers (CRP and IL-6) after stopping CPT compared to those who continued CPT.

40 gs were made 'on' deep brain stimulation and after stopping deep brain stimulation for 2 days.

41 /- 0.36 mug/kg/min while on propofol 8 hours after stopping dexmedetomidine (p < 0.005).

42 MT discontinuation; follow-up for >/=3 years after stopping DMT; not restarting DMT for >/=3 months a

43 5 daily doses, and remained >90% for 7 days after stopping drug from steady-state conditions.

44 l against the reemergence of LF transmission after stopping drug treatments.

45 After stopping DVR, 2 of 63 viruses had emergent G190G/A

46 point, sustained unresponsiveness at 4 weeks after stopping early intervention oral immunotherapy (4-

47 The median time to recurrence was 25 months after stopping erlotinib.

48 Within 1 year after stopping ETV therapy, "clinical relapse" (an episo

49 iral decline and appeared to prevent relapse after stopping ETV.

50 Formation of these inclusions is reversible after stopping expression of the expanded CGG RNA at an

51 cle pain and weakness persisted for 2 months after stopping fluoxetine.

52 t 85 percent of patients died within 15 days after stopping food and fluids.

53 usually die a "good" death within two weeks after stopping food and fluids.

54 so demonstrated a decline in platelet counts after stopping heparin, warfarin-associated supratherape

55 g heparin anticoagulation, and platelet fall after stopping heparin.

56 There was no significant increase in risk after stopping HETs that deplete B-cells (anti-CD20 ther

57 the risk of relapse increased significantly after stopping HETs that impact immune cell trafficking

58 ubsequent treatment an average of 0.3 months after stopping ibrutinib with a median OS of 5.8 months

59 biochemical and histological criteria 1 year after stopping immunosuppression.

60 the period between starting use and 10 years after stopping increases with age at last use: for examp

61 Importantly, at 1 year after stopping induction therapy, response was sustained

62 R 1,500 microg, IL-4R 500 microg, or placebo after stopping inhaled corticosteroids.

63 However, after stopping lamivudine in groups 2 and 3, serum HBV D

64 (18)F(-) PET spine scans at 0, 6, and 12 mo after stopping long-term bisphosphonate treatment were u

65 ve study investigated viral and host markers after stopping long-term therapy with nucleos(t)ide anal

66 After stopping maraviroc, they were followed for an addi

67 After stopping mechanical ventilation in the operating r

68 nderpins behaviors that occur in rats months after stopping methamphetamine self-administration.

69 Progenitors continued to divide after stopping migration, generating clusters of related

70 nts occurred within 1 year (20 of 25; 80.0%) after stopping NA.

71 atients experiencing severe hepatitis flares after stopping nucleot(s)ide analogues (NAs) therapy.

72 f 24 successfully passed a challenge 1 month after stopping OIT and achieved sustained unresponsivene

73 tolerated 2000 mg of peanut protein 6 weeks after stopping omalizumab versus 1 (12%) of 8 receiving

74 e, we reported a low rate of acute rejection after stopping or markedly lowering immunosuppression.

75 months of oxygen treatment, and for 3 months after stopping oxygen.

76 Even after stopping peanut consumption for 5 years, there con

77 drug concentrations persist for several days after stopping PrEP, a reasonable recommendation is to c

78 fect on mossy fiber sprouting was reversible after stopping rapamycin and did not directly correlate

79 toothed whales, females can live for decades after stopping reproduction.

80 , and this response remained elevated 1 week after stopping RIPC; however, NO-mediated vasodilatation

81 The extent of IH after stopping routine caffeine treatment and the potent

82 ome loss of cardiometabolic benefit occurred after stopping semaglutide, similar to the general popul

83 1 patients with CABG performed within 7 days after stopping study drug, reviewers blinded to treatmen

84 llenge to 4000 mg of peanut protein 12 weeks after stopping study drug.

85 all randomised patients for at least 1 year after stopping study treatment.

86 but were still significant at least 5 years after stopping tamoxifen therapy (RR per year of use, 0.

87 surviving patients achieved tubular recovery after stopping tenofovir (mean: 13 weeks).

88 bined oral contraceptives and in the 5 years after stopping than women who began use at older ages, b

89 Wake-up times after stopping the drug were assessed by blinded and unb

90 Alopecia occurred in 2 subjects (reversed after stopping the drug), but otherwise no changes were

91 After stopping the enzyme reaction, compounds were extra

92 insulin sensitivity was observed within 4 h after stopping the indinavir infusion.

93 After stopping the infliximab for infusion-related react

94 nal blood samples were obtained up to 24 hrs after stopping the infusion and analyzed for propofol co

95 verse events, the majority of which occurred after stopping the infusion.

96 6 weeks after stopping the intervention the effect waned (7.3 m

97 Effects were sustained for many years after stopping the intervention.

98 r longer-term follow up of the outcome (even after stopping the medication of interest).

99 c effects appear to persist in some patients after stopping the medication.

100 le of a spheroid degrading over several days after stopping the nutrient supply.

101 midine; hypnotic response had normalized 8 d after stopping the ODNs.

102 as change in esophageal inflammation 2 weeks after stopping the PPI medication, determined by compari

103 Two weeks after stopping the PPI medication, esophageal acid expos

104 line (taking PPIs) and at 1 week and 2 weeks after stopping the PPI medication.

105 y from sedation (COMFORT score of > or = 27) after stopping the propofol infusion was rapid, averagin

106 In 13 patients who were extubated after stopping the propofol infusion, the time to extuba

107 After stopping the randomly allocated treatment, 26 129

108 After stopping the reaction that uses [14C]glucose 1-pho

109 zumab group had a relapse in the first month after stopping the study drug, of whom 7 had ADAMTS13 ac

110 Functional recovery persists even after stopping the treatment at 6 weeks following a stro

111 There was no evidence of rebound after stopping the treatment.

112 of patients with HCV RNA <15 IU/mL 12 weeks after stopping therapy (sustained virologic response [SV

113 f patients with HCV RNA </=15 IU/mL 12 weeks after stopping therapy (sustained virologic response at

114 of patients with HCV RNA <15 IU/mL 12 weeks after stopping therapy (SVR12).

115 patients were followed for at least 48 weeks after stopping therapy and 9 underwent repeat liver biop

116 ion did not address was what would transpire after stopping therapy and whether these events would be

117 titis B viral DNA levels with slower rebound after stopping therapy than has been reported with lamiv

118 lack of detectable HCV RNA at least 24 weeks after stopping therapy).

119 After stopping therapy, 13 of 15 patients experienced a

120 At 4 wk after stopping therapy, HBV replication rebounded but no

121 ts suffered progressive disease on study and after stopping therapy, respectively.

122 eeks and followed for an additional 24 weeks after stopping therapy.

123 that go on to develop hepatic flares 6-18 wk after stopping therapy.

124 ) with HBV DNA levels <=1,000 IU/mL 48 weeks after stopping therapy.

125 of investigational therapies, and follow-up after stopping therapy.

126 s of treatment experienced virologic relapse after stopping therapy.

127 dose, a repeat DBPCFC was performed 3 months after stopping therapy.

128 unknown whether clinical protection persists after stopping therapy.

129 seroconverters may not have durable response after stopping therapy.

130 ined oral contraceptives and in the 10 years after stopping there is a small increase in the relative

131 sis demonstrated that loss of MR4.5 3 months after stopping TKI was predictive of failure to maintain

132 DESIGN, SETTING, AND PARTICIPANTS: The Life After Stopping TKIs (LAST) study was a prospective singl

133 n the aminotransferase level were reversible after stopping tolvaptan.

134 After stopping TPA application, partial skin tumor regre

135 After stopping trastuzumab, the majority of patients who

136 was sustained virological response 12 weeks after stopping treatment (SVR12).

137 ined undetectable HBV DNA without HBsAg loss after stopping treatment an intermediate goal.

138 Virus rebounds after stopping treatment from the stable HBV covalently-

139 Mean (SD) follow-up after stopping treatment with clopidogrel was 196 (152)

140 idogrel treatment, the first 90-day interval after stopping treatment with clopidogrel was associated

141 rtality or acute myocardial infarction (AMI) after stopping treatment with clopidogrel.

142 ys, and 9.7% (n = 26) during 181 to 270 days after stopping treatment with clopidogrel.

143 to examine introduction of allergenic foods after stopping treatment with omalizumab.

144 delayed awakening in the intensive care unit after stopping treatment with sedatives.

145 After stopping treatment, follow-up cognitive testing an

146 At week 104, one year after stopping treatment, the primary end point TNSS AUC

147 hould be undetectable serum HDV RNA 6 months after stopping treatment.

148 observation period, except for one that died after stopping treatment.

149 f failure at the end of treatment or relapse after stopping treatment.

150 increase in risk that persists for one year after stopping treatment.

151 n humans; however, disease relapse is common after stopping treatments.

152 uggest that the risk of molecular recurrence after stopping tyrosine kinase inhibitor (TKI) treatment

153 returned to baseline dimensions about 20 min after stopping US.

154 ing breast cancer diagnosed 10 or more years after stopping use (relative risk 1.01 [0.96-1.05], NS).

155 s number of cancers diagnosed up to 10 years after stopping use is 0.5 (95 percent CI 0.3-0.7), 1.5 (

156 pretreated high-risk SKH-1 mice for 23 weeks after stopping UVB treatment decreased the number of tum

157 TKi (ibrutinib, n = 21; zanubrutinib, n = 2) after stopping venetoclax because of progressive disease

158 ther specific situations before, during, and after stopping venom immunotherapy.

159 Arrest occurred 3-27 min after stopping ventilation.

160 avirenz induction persists for several weeks after stopping, which could potentially select for dolut